Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Caveated Boost For Me-Toos And PBMs In New Net Price Competition Study

Executive Summary

PBMs are able to leverage brand-to-brand competition across a variety of drug classes to lower costs, but that achievement and the presence of me-too drugs is more complicated than what might on its surface look like a clear win for the US health system.

You may also be interested in...



Down But Not Out: The Pharma Policies That Still May Ride With Senate Finance’s PBM Reform

A new biosimilar payment boost, a true, but more limited patient-directed pass-through rebate plan, and product hopping legislation are among the more than two-dozen amendments that could be added to the Senate Finance Committee’s PBM reform package. 

Medicare Price Negotiation Will Disrupt Rebating In Part D; The Question Is How Much

Congressional Budget Office maps out how current rebating practices may change in Medicare Part D under the drug pricing provisions of the Inflation Reduction Act.

US Medicare Part D Inflation Is Real, MedPAC Rebate Data Show

The US Medicare Payment Advisory Commission shares its first looks at the impact of rebates in the Medicare Part D program. Rebates do indeed distort the overall spending trends, the analyses suggest – but underlying prices are still increasing relatively quickly.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel